Journal of the Formosan Medical Association最新文献

Endoscopic and novel approaches for evaluation of indeterminate biliary strictures. 评估不确定胆道狭窄的内镜和新方法。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-27 DOI: 10.1016/j.jfma.2025.05.036

Tung-Yen Lin, Chieh-Chang Chen, Yu-Ting Kuo, Wei-Chih Liao

{"title":"Endoscopic and novel approaches for evaluation of indeterminate biliary strictures.","authors":"Tung-Yen Lin, Chieh-Chang Chen, Yu-Ting Kuo, Wei-Chih Liao","doi":"10.1016/j.jfma.2025.05.036","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.05.036","url":null,"abstract":"Indeterminate biliary strictures are defined as strictures which evade definitive diagnosis after endoscopic retrograde cholangiopancreatography (ERCP)-assisted sampling with brush cytology and/or forceps biopsy and pose significant clinical challenges. While most indeterminate biliary strictures are attributed to malignancies, up to one-third are benign strictures. False-negative and false-positive diagnoses lead to delayed or inappropriate treatment with untoward clinical consequences. Peroral cholangioscopy (POC) and single-operator cholangioscopy (SOC) have demonstrated superior diagnostic accuracy over traditional ERCP-based techniques through enhanced visualization and targeted biopsy. Endoscopic ultrasound (EUS)-guided tissue sampling also achieves superior sensitivity and diagnostic accuracy compared with ERCP-based tissue sampling. The 2025 ESGE guideline proposes an algorithm for optimizing the utilization of ERCP-based and EUS-guided tissue sampling and cholangioscopy with consideration of the stricture location. Furthermore, molecular diagnostic tools such as fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) enable the detection of chromosomal and genetic alterations commonly associated with biliary malignancies, thereby enhancing the sensitivity for malignancy. This review summarizes recent advances in the diagnostic work-up of indeterminate biliary strictures and emerging diagnostic strategies and modalities.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients. 远红外治疗改善腹膜透析患者的心血管和感染结局。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-26 DOI: 10.1016/j.jfma.2025.05.028

Fan-Yu Chen, Ann Charis Tan, Szu-Yuan Li, Chih-Yu Yang, Kuo-Hua Lee, Ming-Tsun Tsai, Hsuan Lin, Chyong-Mei Chen, Chih-Ching Lin

{"title":"Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients.","authors":"Fan-Yu Chen, Ann Charis Tan, Szu-Yuan Li, Chih-Yu Yang, Kuo-Hua Lee, Ming-Tsun Tsai, Hsuan Lin, Chyong-Mei Chen, Chih-Ching Lin","doi":"10.1016/j.jfma.2025.05.028","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.05.028","url":null,"abstract":"Introduction: While far-infrared (FIR) therapy has improved the treatment of various diseases, its effects on peritoneal dialysis (PD) remain understudied. The study aims to investigate the impact of FIR therapy on the cardiovascular and infectious outcomes in PD patients.Methods: A prospective observational study was conducted for six months, comparing a group receiving FIR therapy (n = 49) with a control group (n = 50). The primary outcome is defined as the composite outcome of three-point major adverse cardiovascular events (3P-MACE), coronary artery disease (CAD), congestive heart failure (CHF), or PD-related infection. The secondary outcomes are: (1) 3P-MACE; (2) 3P-MACE, CAD, or CHF; (3) PD-related infection.Results: The FIR group consistently exhibited lower incidence rates for primary and secondary outcomes. The primary outcome occurred in six patients (12.2 %) in the FIR group and 15 patients (30 %) in the control group, with incidence rates of 0.26 vs. 0.75 events per patient-year, respectively (p = 0.03). The secondary outcomes for the FIR and control groups were: (1) 3P-MACE occurred in zero patients and four patients (8 %), respectively; (2) composite outcome of 3P-MACE, CAD, or CHF occurred in two patients (4.1 %) and six patients (12 %), respectively; (3) PD-related infection occurred in six patients (12.2 %) and 12 patients (24 %), respectively. Furthermore, FIR therapy significantly reduced hospitalizations for the primary outcome (HR = 0.22; 95 % CI = 0.07-0.71; p = 0.01) and demonstrated better survival rate at six months (85.7 % vs. 67.9 %, respectively).Conclusion: This study suggests that FIR therapy shows promise in reducing hospitalizations associated with cardiovascular and infectious outcomes in PD patients.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's reply: Post-operative oropharyngeal rehabilitation suppress oxidative stress and inflammation in obstructive sleep apnea patients with transoral robotic surgery. 作者回复：经口机器人手术的阻塞性睡眠呼吸暂停患者术后口咽康复可抑制氧化应激和炎症。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-24 DOI: 10.1016/j.jfma.2025.05.027

Yi-Ju Lai, Kun-Ling Tsai, Ching-Hsia Hung, Cheng-Yu Lin

引用次数: 0

BGMP: a comprehensive database of human blood group gene mutations and phenotypes. BGMP：人类血型基因突变和表型的综合数据库。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-24 DOI: 10.1016/j.jfma.2025.05.029

Chengyan Gao, Wenqian Yu, Can Lou, Hang Lei, Shenglin Huang, Xuefeng Wang, Jiaming Li, Xiaohong Cai

{"title":"BGMP: a comprehensive database of human blood group gene mutations and phenotypes.","authors":"Chengyan Gao, Wenqian Yu, Can Lou, Hang Lei, Shenglin Huang, Xuefeng Wang, Jiaming Li, Xiaohong Cai","doi":"10.1016/j.jfma.2025.05.029","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.05.029","url":null,"abstract":"The BGMP Database (http://bloodgmp.org) serves as a centralized genomic resource for the comprehensive characterization of human blood group systems. Developed to address critical gaps in existing repositories, this platform advances precision in transfusion medicine and compatibility research by integrating classical blood group data with understudied antigen systems, including human neutrophil antigen (HNA), platelet antigens (including human platelet antigens (HPA) and CD36 variants), and immunoglobulin (Ig) allotypes. BGMP consolidates curated data encompassing 47 erythrocyte blood group systems (54 related genes) with phenotype-frequency correlations, 5 human neutrophil antigen (HNA) systems with 25 characterized epitopes, 41 HPA across 7 glycoprotein targets, CD36 deficiency variants (99 mutation profiles), and 3 immunoglobulin allotype systems with 70 serum protein polymorphisms. The database provides tools for allele variant mapping and data visualization. A dedicated submission portal enables researchers to contribute novel allele sequences or population frequency data, which undergo dual validation through automated pipeline checks and manual curation prior to integration. The current release (Version 1.0, 2025) aggregates 2785 annotated variants across all blood group systems, providing a comprehensive resource that supports clinical transfusion practices and advances blood compatibility research.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comments on "Arsenic exposure and trend of incidence in urinary cancer from 1979 to 2019: A nationwide population-based study". 《1979 - 2019年尿路癌人群砷暴露与发病趋势研究》

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-24 DOI: 10.1016/j.jfma.2025.05.034

Yanna Le, Qingyun Xu

引用次数: 0

Comment on Social determinants of health that impact the time to diagnosis and treatment of infertility in Taiwan. 评论影响台湾不孕症诊断和治疗时间的健康社会决定因素。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-23 DOI: 10.1016/j.jfma.2025.05.026

Cao Shanshan, Hu Xueliang

引用次数: 0

Bridging international guidelines on gastroparesis with clinical practice in Taiwan. 衔接国际胃轻瘫指南与台湾临床实践。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-23 DOI: 10.1016/j.jfma.2025.05.025

I-Hsuan Huang, Chien-Lin Chen

引用次数: 0

Reply to comment on "Ablative margin assessment for recurrence prediction in patients with hepatocellular carcinoma receiving radiofrequency ablation". 回复关于“肝细胞癌射频消融患者消融切缘评估预测复发”的评论。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-23 DOI: 10.1016/j.jfma.2025.05.021

Geeng-Jia Hu, Chih-Horng Wu

引用次数: 0

Reply to "Comment on "Exacerbated gastrointestinal symptoms and long COVID in IBD patients with SARS-CoV-2 infection: A multi-center study from Taiwan"". 回复“台湾IBD合并SARS-CoV-2患者胃肠道症状加重及长冠状病毒的多中心研究”评论

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-23 DOI: 10.1016/j.jfma.2025.05.023

Tsung-Yu Tsai, Jia-Horng Kao, Shu-Chen Wei

引用次数: 0

Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis. 老年高血压的血压目标、用药考虑和特殊关注：关注动脉粥样硬化性心血管疾病、心房颤动、心力衰竭和主动脉狭窄。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-05-23 DOI: 10.1016/j.jfma.2025.05.007

Ru-Yin Hsu, Hao-Yun Lo, Chien-Hao Chen, Yee-Jen Wu, Ding-Cheng Chan, Chih-Cheng Wu, Tzung-Dau Wang, Hsien-Li Kao, Wen-Jung Sun, Yen-Hung Lin, Hung-Ju Lin

{"title":"Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.","authors":"Ru-Yin Hsu, Hao-Yun Lo, Chien-Hao Chen, Yee-Jen Wu, Ding-Cheng Chan, Chih-Cheng Wu, Tzung-Dau Wang, Hsien-Li Kao, Wen-Jung Sun, Yen-Hung Lin, Hung-Ju Lin","doi":"10.1016/j.jfma.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.05.007","url":null,"abstract":"The management of hypertension in the elderly, particularly concerning atherosclerotic cardiovascular disease (ASCVD) and comorbidities, is crucial given its prevalence and impact on morbidity and mortality. It is important to individualize pharmacotherapy in elderly patients, including basing the dose on age-related changes in organ function and drug pharmacokinetics. In elderly patients with hypertension and ASCVD, despite slight differences among guideline recommendations, the emphasis is on achieving a systolic blood pressure (BP) < 130 mmHg. The optimal target for patients with atrial fibrillation remains under debate, with suggestions ranging from <130/80 mmHg to <140/90 mmHg. The role of anticoagulation treatment further complicates BP management in these patients. BP targets also differ among guidelines regarding heart failure in the elderly, although maintaining systolic BP < 140/90 mmHg is generally advocated. In hypertensive elderly patients with aortic stenosis, the optimal BP targets are even less clear, and should consider the risks of adverse outcomes. Overall, individualized treatment plans considering age, comorbidities, and tolerability are paramount. Further research is warranted to elucidate optimal BP targets and pharmacotherapeutic strategies tailored to the elderly.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0